The association between IGF-I/IGFBP-3 and subclinical end points: Epidemiology faces the limits

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 8, 2014, Pages 2804-2812

  Müller, Christiane ^a   Wallaschofski, Henri ^a   Brabant, Georg ^b   Wahnschaffe, Ulrich ^c   Samietz, Stefanie ^a   Nauck, Matthias ^a   Friedrich, Nele ^a  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c Evangelisches Waldkrankenhaus Spandau   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ASYMPTOMATIC DISEASES; CARDIOVASCULAR DISEASES; ENDPOINT DETERMINATION; EPIDEMIOLOGIC RESEARCH DESIGN; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IMMUNOASSAY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 84905841517     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3746     Document Type: Article

References (39)

1. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16:3-34.
2. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res. 2003;13: 113-170.
3. Sara VR, Hall K. Insulin-like growth factors and their binding proteins. Physiol Rev. 1990;70:591-614.
4. Yakar S, Rosen CJ, Beamer WG, et al. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest. 2002;110: 771-781.
5. Carro E, Torres-Aleman I. Serum insulin-like growth factor I in brain function. Keio J Med. 2006;55:59-63.
6. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007;28:20-47.
7. Goodman-Gruen D, Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. Am J Epidemiol. 1997;145:970-976.
8. Friedrich N, Jorgensen T, Juul A, et al. Insulin-like growth factor I and anthropometric parameters in a Danish population. Exp Clin Endocrinol Diabetes. 2012;120:171-174.
9. Friedrich N, Rosskopf D, Brabant G, Völzke H, Nauck M, Wallaschofski H. Associations of anthropometric parameters with serum TSH, prolactin, IGF-I, and testosterone levels: results of the study of health in Pomerania (SHIP). Exp Clin Endocrinol Diabetes. 2010; 118:266-273.
10. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation. 2002;106:939-944.
11. Vasan RS, Sullivan LM, D'Agostino RB, et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann Intern Med. 2003;139:642-648.
12. Lin Y, Tamakoshi A, Kikuchi S, et al. Serum insulin-like growth factor-I, insulin-like growth factor binding protein-3, and the risk of pancreatic cancer death. Int J Cancer. 2004;110:584-588.
13. Vadgama JV, WuY, Datta G, Khan H, Chillar R. Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology. 1999;57:330-340.
14. Wakai K, Ito Y, Suzuki K, et al. Serum insulin-like growth factors, insulin-like growth factor-binding protein-3, and risk of lung cancer death: a case-control study nested in the Japan Collaborative Cohort (JACC) Study. Jpn J Cancer Res. 2002;93:1279-1286.
15. Burgers AM, Biermasz NR, Schoones JW, et al. Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality. J Clin Endocrinol Metab. 2011;96:2912-2920.
16. Granada ML, Ulied A, Casanueva FF, et al. Serum IGF-I measured by four different immunoassays in patients with adultGHdeficiency or acromegaly and in a control population. Clin Endocrinol (Oxf). 2008;68:942-950.
17. Krebs A, Wallaschofski H, Spilcke-Liss E, et al. Five commercially available insulin-like growth factor I (IGF-I) assays in comparison to the former Nichols Advantage IGF-I in a growth hormone treated population. Clin Chem Lab Med. 2008;46:1776-1783.
18. Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol (Oxf). 2007;67:65-70.
19. Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem. 2011;57:555-559.
20. Spilcke-Liss E, Friedrich N, Dorr M, et al. Serum insulin-like growth factor I and its binding protein 3 in their relation to intima-media thickness: results of the study of health in Pomerania (SHIP). Clin Endocrinol (Oxf). 2011;75:70-75.
21. Friedrich N, Aumann N, Dörr M, et al. Lack of association between insulin-like growth factor-1 or insulin-like growth factor-binding protein-3 and left ventricular hypertrophy: results of the Study of Health in Pomerania. J Hypertens. 2010;28:856-864.
22. Kaplan RC, Petersen AK, Chen MH, et al. A genome-wide association study identifies novel loci associated with circulating IGF-I and IGFBP-3. Hum Mol Genet. 2011;20:1241-1251.
23. Friedrich N, Haring R, Nauck M, et al. Mortality and serum insulinlike growth factor (IGF)-I and IGF binding protein 3 concentrations. J Clin Endocrinol Metab. 2009;94:1732-1739.
24. John U, Greiner B, Hensel E, et al. Study of Health In Pomerania (SHIP): a health examination survey in an east German region: objectives and design. Soz Praventivmed. 2001;46:186-194.
25. Völzke H, Alte D, Schmidt CO, et al. Cohort profile: the Study of Health in Pomerania. Int J Epidemiol. 2011;40:294-307.
26. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450-458.
27. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18: 1440-1463.
28. Abs R, Bengtsson BA, Hernberg-Stahl E, et al. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol (Oxf). 1999;50:703-713.
29. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7:79-108.
30. Markus MR, Stritzke J, Lieb W, et al. Implications of persistent prehypertension for ageing-related changes in left ventricular geometry and function: the MONICA/KORA Augsburg study. J Hypertens. 2008;26:2040-2049.
31. Luedemann J, Schminke U, Berger K, et al. Association between behavior-dependent cardiovascular risk factors and asymptomatic carotid atherosclerosis in a general population. Stroke. 2002;33: 2929-2935.
32. Bidlingmaier M, Friedrich N, Emeny RT, et al. Reference intervals for insulin-like growth-factor-I (IGF-I) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab. 2014;99(5):1712-1721.
33. Friedrich N, Wolthers OD, Arafat AM, et al. [ahead of print] Age and sex specific reference intervals across life-span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I/IGFBP-3 ratio measured by new automated chemiluminescence assays. J Clin Endocrinol Metab. 2014;99(5):1675-1686.
34. Novo G, Di Miceli R, Orlando D, et al. Carotid intima-media thickness measurement through semi-automated detection software and analysis of vascular walls. Int Angiol. 2013;32:349-353.
35. Alfakih K, Bloomer T, Bainbridge S, et al. A comparison of left ventricular mass between two-dimensional echocardiography, using fundamental and tissue harmonic imaging, and cardiac MRI in patients with hypertension. Eur J Radiol. 2004;52:103-109.
36. WoodwardM.Epidemiology: Study Design and Data Analysis. 2nd ed. Boca Raton, FL: Chapman, Hall/CRC; 2005.
37. Ito Y, Nakachi K, Imai K, et al. Stability of frozen serum levels of insulin-like growth factor-I, insulin-like growth factor-II, insulinlike growth factor binding protein-3, transforming growth factor α, soluble Fas, and superoxide dismutase activity for the JACC study. J Epidemiol. 2005;15(suppl1):S67-S73.
38. Greg Miller W, Myers GL, Lou Gantzer M, et al. Roadmap for harmonization of clinical laboratory measurement procedures. Clin Chem. 2011;57:1108-1117.
39. Frystyk J, Freda P, Clemmons DR. The current status of IGF-I assays- a 2009 update. Growth Horm IGF Res. 2010;20:8-18.